<DOC>
	<DOCNO>NCT01027481</DOCNO>
	<brief_summary>In recent study could show early retinal venous vasoconstriction grid photocoagulation branch retinal vein occlusion ( BRVO ) closely correlate visual outcome three month . This could clinical importance , degree vasoconstriction might early marker treatment success , compatible idea hypoxia major trigger VEGF BRVO . The present study evaluate response retinal vessel diameter anti VEGF treatment lucentis patient BRVO . This do effort gain insight retinal hemodynamic consequence anti VEGF treatment BRVO . The hypothesis anti VEGF treatment associate vasoconstrictor response retinal vessel patient BRVO test .</brief_summary>
	<brief_title>Ranibizumab Patients With Branch Retinal Vein Occlusion</brief_title>
	<detailed_description>To investigate response retinal vessel diameter lucentis treatment patient BRVO correlate change change functional outcome 3 month . Pilot study patient schedule intravitreal anti-VEGF ( Lucentis™ ) treatment BRVO 30 patient BRVO schedule intravitreal anti-VEGF treatment Intravitreous administration Ranibizumab ( Lucentis ™ ) Main outcome measure : Retinal vessel diameter Secondary outcome measure : Retrobulbar flow velocity , best-corrected visual acuity , macular sensitivity assess Microperimetry , objective functional response assess mfERG , anatomic change macula region assess StratusOCT prototype Cirrus-OCT ( available Department Ophthalmology , Medical University Vienna ) , angiographical outcome .</detailed_description>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>male female , least 18 year age . ophthalmoscopic evidence recent BRVO , , history 3 month . macular edema secondary BRVO study eye schedule intravittreal antiVEGF primary treatment . retinal thickness &gt; 300 µm OCT central subfield study eye baseline . VA decrease attributable edema . write informed consent obtain . female patient childbearing potential must negative urine pregnancy test . Uncontrolled sytemic disease Symptoms clinically relevant illness 3 week first study day Any ocular condition opinion investigator would prevent 15letter improvement visual acuity ( eg severe macular ischemia ) History glaucoma , aphakie presence anterior chamber intraocular lens , active reinal neovascularisation , choroidal neovascularisation , significant cataract , presence rubeosis iridis , ocular infection , history par plana vitrectomy , anticipate need ocular surgery study eye study perios . contraindication pupil dilation know allergy contraindication use fluorescein .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>lucentis , macular edema , branch retinal vein occlusion</keyword>
</DOC>